جستجوی استاد راهنمای دانشگاهی

Un J. Kang, MD is the Founders Professor of Neurology at NYU Grossman School of Medicine and Professor in the Department of Neuroscience and Physiology. He serves as Director of Translational Research at the Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders and Co-Director of the Parekh Center for Interdisciplinary Neurology. His clinical practice focuses on Parkinson's disease and related movement disorders including tremor, dystonia, and Huntington's disease. Dr. Kang earned his MD from Johns Hopkins University in 1982, completed residency in Neurology at NY Presbyterian - Columbia University Medical Center in 1986, and specialized in Movement Disorders through fellowship training at the same institution in 1987. His research investigates the pathogenesis of Parkinson's disease and mechanisms of therapy, with particular focus on basal ganglia circuit plasticity, neural adaptation to dopamine loss, and development of biomarkers for neurodegenerative disorders. He pioneered experimental gene therapy approaches for Parkinson's disease and now directs the Kang Lab where his team studies how brain circuitry is perturbed by dopamine loss and pharmacological treatment in mouse models. Dr. Kang's research portfolio includes multiple NIH-funded projects examining striatal cholinergic interneuron dysfunction, freezing of gait mechanisms, and biomarker development for Parkinson's disease. His laboratory has published extensively on Parkinson's disease mechanisms with 178 publications to date, including significant recent work on alpha-synuclein detection methods and striatal pathway alterations in Parkinsonian motor deficits. Before joining NYU Langone in 2019, Dr. Kang created and led a multidisciplinary research team at the University of Chicago for two decades and previously served as chief of the movement disorders division at Columbia University. He leads the BioFIND consortium as principal investigator, banking biospecimens for Parkinson's disease biomarker discovery.

• Parkinson's disease
• Movement disorders
• Basal ganglia circuit
• +۶ مورد دیگر

Dr. Rebecca San Gil is a Lecturer at the School of Medical Sciences , University of Sydney, Australia. She leads the NeuroMolecular Discovery Group within the Neuroscience theme and is a member of the Charles Perkins Centre . Her research focuses on the molecular mechanisms underlying neurodegenerative diseases such as motor neuron disease (MND) and frontotemporal dementia (FTD) , with an emphasis on protein aggregation, stress responses, and therapeutic discovery. PhD, University of Wollongong (2018) Postdoctoral Research, Queensland Brain Institute (2018–2025) Endeavour Research Fellow (University College London) Her research spans molecular biology , neurosciences , and biochemistry , integrating techniques like genome-wide CRISPR screening , multi-omics analysis , and translational research . Key themes include the role of molecular chaperones , heat shock response , and protein folding dynamics in mitigating neurodegeneration. Dr. San Gil’s recent publications (2016–2025) highlight her work on TDP-43 pathology , heat shock proteins , and therapeutic strategies across ALS/FTD models. She has received awards such as the FightMND Early Career Research Fellow and the Sydney Dementia Network Future Research Leader Award (Travel Support Scheme) in 2025. Scientific Awards : FightMND Early Career Research Fellow, Sydney Dementia Network Future Research Leader Award (2025) Dr. San Gil actively mentors researchers like Celine CHYE and collaborates with institutions globally. Her team welcomes new members to explore neurodegenerative disease biology and therapeutic discovery .

• Neurodegenerative Diseases
• Motor Neuron Disease (MND)
• Frontotemporal Dementia (FTD)
• +۷ مورد دیگر

Caryl E. Sortwell is a Professor of Translational Neuroscience and Edwin A. Brophy Endowed Chair in Central Nervous System Disorders at Michigan State University's College of Human Medicine. She leads the Sortwell Lab within the Neuroscience Program and Grand Rapids Research Center, focusing on Parkinson's disease (PD) therapeutics. Education : B.S. in Psychology/Pre-medicine (University of Illinois, 1987), Ph.D. in Anatomy and Cell Biology/Neurobiology (University of Illinois at Chicago, 1994) Positions : Assistant/Associate Professor at Rush University Medical Center (1997-2005), Associate Professor at University of Cincinnati (2005-2009), Professor at MSU College of Human Medicine (2009-present) Her research investigates alpha-synuclein pathology in PD using preformed fibril models to study neurodegeneration, neuroinflammation, and therapeutic interventions. She explores neurotrophic factors like BDNF, gene therapies targeting CaV1.3 channels, and deep brain stimulation mechanisms. Her work emphasizes precision medicine approaches to optimize treatment outcomes. Scientific contributions include methodological advancements in neurochemical sensing with diamond electrodes and viral vector delivery systems. Key collaborations include research with Dr. Joe Patterson on alpha-synuclein genetic consequences. Technical Expertise : Immunohistochemistry, stereotactic surgery, in vivo neurotoxicant models, protein analysis (Western blot/ELISA), droplet digital PCR, and neuroinflammatory profiling

• Parkinson's Disease
• Neurotrophic Factors
• Alpha-Synuclein Pathology
• +۴ مورد دیگر

Hideyuki Takahashi is an Associate Research Scientist in the Department of Neuroscience at Yale University School of Medicine. He holds a PhD from Waseda University (2005) and has established himself as a prominent researcher in neurodegenerative diseases, particularly focusing on lysosomal biology and protein aggregation mechanisms. Dr. Takahashi's research primarily investigates the role of progranulin, TMEM106B, and other molecular players in neurodegenerative conditions including Alzheimer's disease, frontotemporal dementia, and tauopathies. His work spans multiple approaches from molecular and cellular neuroscience to animal models of disease. His recent publications demonstrate a strong focus on lysosomal dysfunction in neurodegeneration, with particular attention to how TMEM106B interacts with other proteins to influence disease progression. The research trends show increasing emphasis on therapeutic interventions targeting specific molecular pathways involved in protein aggregation and synaptic loss. ORCID: 0009-0004-4969-977X Dr. Takahashi maintains active collaborations with several leading researchers at Yale, most notably with Stephen Strittmatter (with whom he has 16 common publications), as well as Anita Huttner, Anthony Koleske, and Le Zhang. His research program appears well-integrated within Yale's neuroscience community, contributing significantly to our understanding of neurodegenerative disease mechanisms.

• Neuroscience
• Neurodegenerative Diseases
• Alzheimer's Disease
• +۳ مورد دیگر

Manu Sharma is an Associate Professor of Neuroscience at the Brain and Mind Research Institute , Weill Cornell Medical College (2024–present). His research focuses on the molecular mechanisms underlying neurodegenerative diseases, particularly tauopathies and synucleinopathies (e.g., Alzheimer’s and Parkinson’s diseases), synaptic transmission, and protein aggregation. Education: Ph.D., University of Toronto (2005) B.Sc., University of Toronto (1998) Research Interests: Dr. Sharma investigates how physiological and pathological modifications of tau and α-synuclein proteins contribute to neurodegeneration. His work explores synaptic vesicle dynamics, chaperone-mediated protein stabilization, and the role of lysosomal pathways in disease progression. Grants: He has secured major funding as Principal Investigator and Co-Investigator from the National Institute on Aging and National Institute of Neurological Disorders & Stroke (2024–2029) for studies on tau proteostasis, synucleinopathies, and small molecule inhibitors targeting neurodegenerative pathways. Labs & Teams: Affiliated with the Brain and Mind Research Institute, Dr. Sharma collaborates on multidisciplinary projects involving synaptic biology, protein quality control, and neurodegeneration models.

• Neuroscience
• Neurodegenerative Diseases
• Synaptic Transmission
• +۵ مورد دیگر

Pam J. McLean, Ph.D. is a Professor of Neuroscience and Consultant in the Department of Neuroscience at Mayo Clinic, Jacksonville, Florida . She leads the Neurobiology of Parkinson's Disease and Related Disorders Laboratory , focusing on the molecular mechanisms of neurodegenerative diseases such as Parkinson’s disease and dementia with Lewy bodies. Primary Appointment: Consultant, Department of Neuroscience Institution: Mayo Clinic, Jacksonville, FL Research Affiliations: APDA Center for Advanced Research, Center for Clinical and Translational Science (CCaTS), Discovery and Translation Labs: Brain Research, Lewy Body Dementia Center Without Walls Dr. McLean’s research centers on alpha-synuclein , a key protein involved in neurodegeneration. Her lab investigates how alpha-synuclein misfolds, aggregates, and propagates in a prion-like manner across neurons, contributing to disease progression. She employs human induced pluripotent stem cell models, viral vector-based systems, and animal models to study these processes. Key research themes include: Prion-like propagation of alpha-synuclein Biomarker discovery using extracellular vesicles in blood Copathologies in neurodegenerative diseases Development of gene therapies and small molecules targeting alpha-synuclein Her recent publications highlight work on alpha-synuclein seeding assays, transcriptional differences between Lewy body disease and Alzheimer’s, and novel methods for isolating plasma-derived extracellular vesicles for diagnostic use. These reflect a strong trend toward translational neuroscience, aiming to bridge molecular insights with clinical applications. Dr. McLean is actively funded through multiple NIH grants, including from the National Institute on Aging and the National Institute of Neurological Disorders and Stroke. She serves as Principal Investigator on projects related to functional assessment of pathological species in Lewy body dementia and contributes to the Mayo Alzheimer’s Disease Research Center. Her lab is committed to patient-centered research and training the next generation of neuroscientists, offering postdoctoral fellowships and research education programs. She collaborates extensively with experts in neuropathology, neurology, and translational biology.

• Neurodegenerative Diseases
• Parkinson's Disease
• Dementia with Lewy Bodies
• +۱۲ مورد دیگر

Sang-Hyun Oh is Distinguished McKnight University Professor and Sanford P. Bordeau Chair in Electrical and Computer Engineering at University of Minnesota. His research develops nano-optical tools for biomedical applications, specializing in plasmonic biosensors, nanophotonic devices, and optical manipulation techniques. Key innovations include nanofluidic platforms for single-molecule analysis, high-Q metasurfaces for vibrational spectroscopy, and waveguide-integrated optical tweezers. Recent projects focus on diagnostic technologies such as Nano-QuIC for Parkinson's detection and computational design of upconversion materials. His laboratory advances nanofabrication methods including template stripping and atomic-layer lithography to create plasmonic nanostructures with atomic-scale precision. Collaborative projects bridge photonics, neuroscience, and clinical medicine to develop next-generation biosensors.

• Nanophotonics
• Plasmonics
• Biosensing
• +۲ مورد دیگر

Dr. Boubker Zaaimi is a Lecturer in Neuroscience at Aston University, affiliated with the School of Life & Health Sciences under the College of Health and Life Sciences. His 15+ years of experience focus on implanting electrodes in animal models (rodents to primates) to study brain activity modulation, particularly in stroke and epilepsy contexts. He specializes in brain-machine interfaces, optogenetics, and closed-loop protocols to regulate neural activity. Key projects include the CANDO project (Newcastle University) and collaborations with DARPA and industry partners like Autifony Therapeutics. His research uses magnetoencephalography (MEG) to advance human brain activity recording and modulation techniques. Employment History: Multiple postdoctoral roles at Newcastle University, Northwestern University, and City College, NY, culminating in his current faculty position. Research Interests: Optogenetic control, neural dynamics in primates, spinal cord plasticity, and neuromodulation therapies. His work bridges basic science and clinical applications, with recent focus on non-invasive neurostimulation (e.g., brain-responsive music) and closed-loop systems for epilepsy management. Over 19 peer-reviewed articles highlight his contributions to understanding neural pathways and developing therapeutic interventions.

• Neuroscience
• Neuromodulation
• Brain-Computer Interfaces
• +۵ مورد دیگر

Simon Tang is a BBSRC Research Fellow and Proleptic Lecturer in the Department of Life Sciences at the University of Bath. He also holds a Visiting Researcher position in the same department. His research is supported by prestigious grants from the Biotechnology and Biological Sciences Research Council (BBSRC) and the Engineering and Physical Sciences Research Council (EPSRC), where he serves as Principal Investigator (PI) and Co-Investigator (CoI) on multiple active projects. His research focuses on advancing sustainable biotechnological solutions for drug discovery, particularly through the engineering of enzymes such as asparaginyl endopeptidases and peptide ligases. Key areas include the intracellular production of cyclic peptides, enzyme compartmentalization, and the development of novel screening platforms for bioactive compounds. The trends in his recent publications reflect a strong emphasis on chemical biology, protein engineering, and enzyme mechanism studies. His work integrates synthetic biology with therapeutic discovery, targeting neurodegenerative diseases and sustainable pharmaceutical development. Scientific Awards: BBSRC Research Fellowship (2025), competitively awarded for innovative work in sustainable cyclic peptide production. Dr. Tang leads independent research projects, including the development of intracellular screening platforms and methods for controlling enzyme activity. He collaborates closely with Prof. Jody Mason and Dr. Luet Luk. While no formal advisees are listed, his leadership roles indicate active mentorship and research supervision. His work contributes to UN Sustainable Development Goals related to good health and sustainable industry. He is associated with research networks in enzyme engineering and peptide therapeutics, with collaborations spanning multiple institutions and countries.

• Biochemistry
• Molecular Biology
• Enzyme Engineering
• +۷ مورد دیگر

Niklas Mattsson-Carlgren serves as an Associate Professor and Senior Lecturer at Lund University's Faculty of Medicine, Department of Clinical Sciences. He holds multiple significant roles including Deputy Research Team Manager and Principal Investigator for several major research projects. His affiliations extend to the Wallenberg Centre for Molecular Medicine (WCMM), LU Profile Area: Proactive Ageing, and MultiPark: Multidisciplinary Research Focused on Parkinson's Disease. Dr. Mattsson-Carlgren's research primarily focuses on Alzheimer's disease and other neurodegenerative conditions, with additional work on acute brain injuries such as those following cardiac arrest. His expertise spans neurochemistry, including the regulation of pain and sleep. He employs biochemical measurements, neuroimaging, and cognitive testing to study disease processes in vivo across the spectrum from preclinical disease to advanced dementia. His work aims to improve diagnostic and prognostic methods in clinical practice, enhance clinical trial design for novel therapies, and deepen understanding of disease mechanisms. His recent publications demonstrate a strong emphasis on plasma biomarkers for Alzheimer's disease detection and monitoring, with particular focus on tau and amyloid pathology. The research shows increasing integration of machine learning approaches with traditional biomarker analysis, reflecting a trend toward more sophisticated diagnostic tools that combine multiple data sources for improved accuracy in predicting disease progression. As Principal Investigator for multiple significant projects including 'Longitudinal plasma biomarkers, cognitive data and amyloid PET to improve early prevention of Alzheimer's disease' and 'Validation of an MTBR tau immunoassay for CSF and plasma,' he leads substantial research efforts funded by organizations including Familjen Rönströms stiftelse, Eli Lilly and Company, and the Knut and Alice Wallenberg Foundation. He also serves as supervisor for PhD students, notably for 'Studies of induced neuronal cells in Alzheimer's disease.' Dr. Mattsson-Carlgren is actively involved in the neuroscience community, serving on the program committee for Neuroscience Day 2025. His research contributes to UN Sustainable Development Goals related to health and wellbeing. His work has gained significant attention, with multiple papers being picked up by news outlets and referenced across social media platforms including X (Twitter) and Bluesky.

• Alzheimer's Disease
• Neurodegenerative Diseases
• Tau Pathology
• +۷ مورد دیگر

Dr. Charles Harrington is a Senior Research Fellow at the University of Aberdeen's School of Medicine, Medical Sciences and Nutrition. With a background in microbiology, he has transitioned to become a leading researcher in neurodegenerative diseases, particularly focusing on Alzheimer's disease and tau protein biology. His career spans over four decades, with significant contributions to understanding the molecular mechanisms of protein aggregation in neurodegenerative conditions. BSc (Hons) Microbiology, University of Glasgow (1977) PhD Microbiology, University of Glasgow (1980) Harrington's research interests center on the biology of tau protein in aging and Alzheimer's disease, with emphasis on diseases characterized by protein aggregation and methods to prevent these processes. His work has evolved from early studies on microbial cell walls to current investigations of tau pathology, demonstrating remarkable interdisciplinary expertise. He has developed assays for screening tau aggregation inhibitors and has extensively studied the therapeutic potential of hydromethylthionine. Analysis of his recent publications (2021-2025) reveals a strong focus on tau protein aggregation mechanisms, neuroinflammation, synaptic dysfunction in neurodegenerative diseases, and the therapeutic effects of tau aggregation inhibitors. His work frequently examines interactions between different therapeutic approaches, particularly how cholinesterase inhibitors might interfere with tau-targeting treatments. Harrington's research bridges molecular mechanisms with clinical applications, contributing significantly to the development of biomarkers and therapeutic strategies for Alzheimer's disease and related tauopathies. As Chief Scientific Officer for TauRx Therapeutics Ltd, Harrington oversees non-clinical activities for a company conducting phase 3 trials of hydromethylthionine. His collaborative work spans multiple international institutions, with numerous co-authors across neuroscience, biochemistry, and clinical research fields. While specific grant information isn't detailed in the provided text, his extensive publication record suggests substantial research funding support over his career. Harrington's laboratory work appears focused on tau transgenic mouse models, particularly investigating how tau pathology affects synaptic function, neurotransmitter systems, and behavioral outcomes. His research team has developed sophisticated methods for studying protein aggregation and its consequences in neurodegenerative disease models.

• Neurodegenerative Diseases
• Alzheimer's Disease
• Tau Protein Biology
• +۳ مورد دیگر

Professor Neil Harrison is a Clinical Professor in Neuroimaging at Cardiff University's School of Medicine, leading the Immunopsychiatry Research Group at CUBRIC and the Haydn Ellis Building. He previously established the UK's first Clinical Immunopsychiatry Service in Sussex. His expertise spans neuroimaging, psychiatry, and immunology, focusing on how immune systems interact with brain function in mental illnesses like depression and Alzheimer’s. He holds grants from the MRC, Wellcome Trust, and Janssen Pharmaceutics. Education: PhD in Neuroscience from UCL’s Wellcome Trust Centre for Neuroimaging, psychiatry training at the Maudsley Hospital and National Hospital for Neurology, Queen Square. Research interests include neuroinflammation’s role in mental health, with a focus on translational approaches like wearable technology for early disease detection. He chairs the Psychoneuroimmunology Research Society and advises the Wellcome Trust’s Clinical Interview Committee. Grants and collaborations include work on imaging brain inflammation, chronic fatigue mechanisms, and translational immunopsychiatry. His lab investigates neuroimaging biomarkers and clinical applications of immunological insights in mental health.

• Immunopsychiatry
• Neuroimaging
• Psychiatry
• +۵ مورد دیگر

Professor Rajesh Ramanathan is a renowned interdisciplinary scientist and research leader at RMIT University's School of Science. He holds the rank of Professor and co-leads the NanoBiotechnology Research Lab (NBRL). His work focuses on nanotechnology, materials chemistry, and sensor development for healthcare applications, with over 85 peer-reviewed publications and 20 patents. He has secured AUD $22 million in research funding and mentored 16 PhD students and 3 postdocs. Education: PhD in Science (RMIT University, 2012), Master of Biotechnology (RMIT, 2006), and Bachelor of Science (Ruia College, 2004). Awards include the Hartung Lecturer Award (2022), Rising Star Award (2022), and Philip Law Postdoctoral Award (2019). Research interests span nanobiotechnology, nanozymes, antimicrobial surfaces, and sensors for environmental/clinical analytes. He leads projects in supercapacitor materials, inflammation theranostics, and UV protection textiles. Current students include Pyria Mariathomas (antibacterial nanozymes) and Shalu Yadav (2D nanocomposites for viral biomarkers). Professional roles include President of the Royal Australian Chemical Institute VIC Branch and leadership roles in the Australian Nanotechnology Network. His work bridges academia and industry, with collaborations in biomedical imaging and sensor commercialization.

• Nanobiotechnology
• Materials Chemistry
• Analytical Chemistry
• +۶ مورد دیگر

Prof. Dr. Jochen Herms serves as Director at the LMU Center for Neuropathology and Prion Research , while maintaining a dual affiliation with the German Center for Neurodegenerative Diseases (DZNE) Munich as Head of Translational Brain Research. His work bridges clinical and experimental neuropathology, focusing on synaptic degeneration in neurodegenerative conditions. Ludwig-Maximilians-Universität München (LMU): Director, Experimental Neuropathology DZNE Munich: Translational Brain Research Research Themes: Primary: Biomedical Neuroscience Secondary: Cellular & Systems Neuroscience Tertiary: Behavioral & Cognitive Neuroscience Key investigations include: Physiological roles of neurodegenerative disease proteins (APP, presenilins, BACE, tau, α-synuclein) In vivo two-photon imaging of transgenic Alzheimer's models Neuronal calcium homeostasis in neurodegeneration High-throughput drug screening for AD/PD Active research collaborations leverage funding from: German Research Foundation (DFG) - Munich Cluster for Systems Neurology (EXC 2145 SyNergy) BMBF, BMWi, EU consortia Bavarian Research Foundation Wilhelm Sander Foundation

• Biomedical Neuroscience
• Cellular & Systems Neuroscience
• Behavioral & Cognitive Neuroscience
• +۵ مورد دیگر

Frédéric Calon is a Full Professor in the Faculty of Pharmacy at Université Laval, where he leads a prominent research program focused on neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s diseases. His work bridges molecular neuroscience, nutritional interventions, and blood-brain barrier drug delivery, using both animal models and human post-mortem studies. He is actively involved in training graduate students and postdoctoral fellows and maintains international collaborations, including the LIA OptiNutriBrain with Bordeaux. B.Sc. in Biochemistry, Université Laval (1989–1992) M.Sc. in Pharmacy, Université Laval (1992–1995) B.Pharm., Université Laval (1994–1998) Ph.D. in Pharmacy, Université Laval (1998–2001) Postdoctoral Training, University of California, Los Angeles (UCLA), Dept. of Medicine (2001–2003) Dr. Calon’s research centers on three main axes: (1) the role of nutrition—especially omega-3 fatty acids—in neurodegeneration; (2) synaptic and molecular pathology in Alzheimer’s and Parkinson’s diseases; and (3) the interplay between peripheral metabolic disorders and brain health, including insulin signaling and thermoregulation. He also investigates the blood-brain barrier as a therapeutic gateway for drug delivery. His recent publications reflect a strong focus on Alzheimer’s disease mechanisms, including tau phosphorylation, amyloid-beta pathology, synaptic dysfunction, and the impact of diet and metabolism. He has also made key contributions to understanding essential tremor through post-mortem brain studies. His work frequently involves transgenic mouse models, such as the 3xTg-AD, and integrates behavioral, biochemical, and imaging techniques. Dr. Calon’s research is supported by major grants from CIHR and the Alzheimer Society of Canada. He mentors a large team of doctoral, master’s, and postdoctoral researchers, many of whom are supported by competitive scholarships. His lab has developed unique expertise in in situ brain perfusion and quantitative BBB transport analysis. He leads studies on novel therapeutic strategies, including repurposing beta-3 adrenergic agonists, optimizing nutraceutical formulations, and enhancing brain delivery of biologics via transferrin receptor-targeted vectors. His work on essential tremor has identified GABA receptor deficits and amyloid-beta accumulation in the cerebellum, suggesting a neurodegenerative basis for the disorder.

• Neurodegenerative Diseases
• Alzheimer's Disease
• Parkinson's Disease
• +۱۲ مورد دیگر